BX795 inhibits the catalytic activity of TBK1/IKKε by blocking their phosphorylation. BX795, an aminopyrimidine compound, was developed as an inhibitor of 3-phosphoinositide-dependent kinase 1 (PDK1) [1]. It was recently shown to be a potent inhibitor of the IKK-related kinases, TANK-binding kinase 1 (TBK1) and IKKε, and hence of IRF3 activation and IFN-β production [2, 3]
Citations:
Recent articles using BX795
2014 - J Immunol., 192(5):2395-404 Inflammatory cytokines break down intrinsic immunological tolerance of human primary keratinocytes to cytosolic DNA. Chiliveru S, Rahbek SH, Jensen SK, Jørgensen SE, Nissen SK, Christiansen SH, Mogensen TH, Jakobsen MR, Iversen L, Johansen C, Paludan SR
2014 - J Immunol., 192(1):492-502 MPYS/STING-mediated TNF-α, not type I IFN, is essential for the mucosal adjuvant activity of (3'-5')-cyclic-di-guanosine-monophosphate in vivo. Blaauboer SM, Gabrielle VD, Jin L
2012 - Hum Gene Ther., 23(10):1090-100 Inhibition of intracellular anti-viral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Sutlu T, Nyström S, Gilljam M, Slan B, Applequist SE, Alici E